Haleon

History

2022: Haleon GSK Separation Plan - as OTC Drug Divisions

On February 22, 2022, GlaxoSmithKline plc announced the name of the company, which will appear on the market in mid-2022 as a result of the allocation of a division of over-the-counter drugs and consumer health products into an independent business. It will conduct its activities under the Haleon brand.

The name Haleon (pronounced "heleon") was inspired by the combination of the words hale and leon. Hale in Old English means "good health," and leon is associated with the word "strength." The development of branding was carried out with the participation of employees, as well as focus groups of doctors and consumers from around the world. The brand will be represented in more than 100 markets in all countries of the company's presence.

The creation of Haleon was the result of a series of investments and strategic transformations by GSK Consumer Healthcare over the past eight years, including the integration of consumer health product portfolios from Novartis and Pfizer. As of February 2022, this is a highly rated global business with an annual sales volume of about 10 billion pounds.

GSK suggests that Haleon will become the world leader in the market for over-the-counter drugs and consumer health products. The peculiarity of the company will be based on a deep understanding of consumers and authoritative scientific research: Haleon has the necessary experience and opportunities to help everyone and society as a whole improve health and quality of life in simple and accessible ways.

The title reflects our goal - to take care of people, helping them to be healthy every day. We are preparing to start work under this brand as an independent market player in mid-2022, and as of February 2022, our business is dynamically developing, "said Brian McNamara, acting CEO of Haleon.

{{quote 'Haleon will focus solely on helping people to be healthy every day. Haleon has great potential to improve the health and quality of life of people around the world, as well as great opportunities for growth. All this creates the prospect of a significant increase in value for shareholders after the completion of the placement on the exchange, "said Emma Walmsley, chief executive officer of GSK. }}

In Russia, Haleon will present famous brands, including Teraflu, Korega, Voltaren, Otrivin, Bifiform, Sensodyne and many others. Having become a new company, we will continue to focus on promoting a responsible attitude to health, which for us, as a company 100% focused on consumer health, is a main priority, "commented Konstantinos Limnidis, CEO of GSK Consumer Healthcare in Russia.